Table 1.
Characteristic | VU, n=14 | CCF, n=29 | UAB, n=25 | Combined, n=68 |
---|---|---|---|---|
Antibiotic dose, g | ||||
2 | 0% (0) | 0% (0) | 84% (21) | 31% (21) |
3 | 100% (14) | 100% (29) | 16% (4) | 69% (47) |
Antibiotic infusion duration, min | ||||
30 | 0% (0) | 100% (29) | 100% (25) | 79% (54) |
240 | 100% (14) | 0% (0) | 0% (0) | 21% (14) |
Antibiotic frequency, h | ||||
6 | 0% (0) | 3% (1) | 96% (24) | 37% (25) |
8 | 79% (11) | 76% (22) | 4% (1) | 50% (34) |
12 | 21% (3) | 21% (6) | 0% (0) | 13% (9) |
CRRT effluent rate, ml/kg per h | 30.9 (28.5–33.0) | 22.8 (20.8–25.3) | 40.0 (28.5–45.5) | 26.6 (23.7–37.0) |
CRRT mode | ||||
CVVH | 36% (5) | 0% (0) | 0% (0) | 7.4% (5) |
CVVHD | 0% (0) | 100% (29) | 0% (0) | 42.6% (29) |
CVVHDF | 64% (9) | 0% (0) | 100% (25) | 50% (34) |
Weight, kg | 99.8 (80.8–118.7) | 100.8 (90.2–125.5) | 88.3 (68.1–105.3) | 96.9 (80.8–116.2) |
Age, yr | 53.5 (47.0–60.5) | 64.0 (55.0–72.0) | 51.0 (40.0–63.0) | 56.5 (50.0–70.0) |
Sex | ||||
Women | 29% (4) | 21% (6) | 56% (14) | 35% (24) |
Men | 71% (10) | 79% (23) | 44% (11) | 65% (44) |
Mortality | 43% (6) | 41% (12) | 52% (13) | 46% (31) |
Piperacillin PK | ||||
V | 27.3 (22.7–31.0) | 34.4 (30.5–44.1) | 33.8 (26.2–40.9) | 33.0 (25.7–40.5) |
k | 0.151 (0.131–0.177) | 0.108 (0.093–0.134) | 0.140 (0.130–0.194) | 0.132 (0.106–0.153) |
Tazobactam PK | ||||
V | 34.5 (30.8–39.1) | 31.4 (24.7–36.6) | 47.8 (39.5–59.0) | 36.6 (28.2–46.1) |
k | 0.102 (0.094–0.112) | 0.079 (0.071–0.091) | 0.115 (0.105–0.124) | 0.096 (0.080–0.113) |
Quantitative values are summarized using medians (interquartile ranges). Categorical variables are summarized using percentages (counts). VU, Vanderbilt University; CCF, Cleveland Clinic Foundation; UAB, University of Alabama at Birmingham; CRRT, continuous RRT; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration; PK, pharmacokinetics; V, volume of distribution; k, elimination rate.